MedTrace Logo

Atorvastatin for the Treatment of Retinal Vein Occlusion

NCT00517257 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2008-06-25

No results posted yet for this study

Summary

The ATORVO study is designed to determine whether atorvastatin (Lipitor) can improve vision, when compared to placebo

Conditions

  • Retinal Vein Occlusion
  • Retinal Vein Thrombosis
  • Central Retinal Vein Occlusion
  • Branch Retinal Vein Occlusion
  • Thrombosis

Interventions

DRUG

Atorvastatin

80 mg orally once daily for 24 weeks

DRUG

Placebo

Placebo tablet orally once daily for 24 weeks

Sponsors & Collaborators

  • Unity Health Toronto

    collaborator OTHER

  • Pfizer

    collaborator INDUSTRY

  • Canadian Heart Research Centre

    collaborator OTHER

  • Ontario Association of Optometrists

    collaborator OTHER

  • Toronto Ophthalmological Society

    collaborator UNKNOWN

  • University of Toronto

    lead OTHER

Principal Investigators

  • Joel G Ray, MD MSc · St. Michael's Hospital, University of Toronto

  • David Wong, MD · St. Michael's Hospital, University of Toronto

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-08-31
Completion
2009-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00517257 on ClinicalTrials.gov